20 Years on Wall Street Taught Me: 5 Large Cap High-Yield Dividend Giants You Never Sell24/7 Wall Street • 12/01/25
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)GlobeNewsWire • 12/01/25
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 YearsThe Motley Fool • 11/27/25
J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/25/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven StrategyBusiness Wire • 11/17/25
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/17/25
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisitionProactive Investors • 11/17/25
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJZacks Investment Research • 11/17/25